AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25141218
Drug: EX (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX (placebo laser therapy plus daily exercises)
Trial: 22381711
Drug: Fimasartan 60/120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 60/120 mg daily
Trial: 22381711
Drug: Losartan 50/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50/100 mg daily
Trial: 17224031
Drug: Test group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group: primary galvanic caps fabricated on implant abutments with a secondary cast noble alloy superstructure luted with resin cement (Nimetic Cem)
Trial: 12518488
Drug: Oral‐B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B CrossAction (control manual toothbrush)
Trial: 26286684
Drug: Positive focussing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive focussing on treatment information
Trial: 26286684
Drug: Negative focussing
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative focussing on treatment information
Trial: 26286684
Drug: Mixed aspects
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed aspects focussing on treatment information
Trial: 15248886
Drug: Delayed-immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-immediate implant placement (Im)
Trial: 15248886
Drug: Delayed single-tooth
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed single-tooth implant placement (De)
Trial: 15248886
Drug: Overall implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall implant treatment satisfaction (both groups)
Trial: 15248886
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of implant surgery
Trial: 11740133
Drug: Thyroxine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine therapy (mean dose 136 +/‐ 22 microg/day)
Trial: 9237937
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of ferrous gluconate (15 mg elemental iron) plus multivitamins
Trial: 8479488
Drug: Dapsone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone (50 mg per day) plus pyrimethamine (50 mg per week)
Trial: 8479488
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine (300 mg per month)
Trial: 30789059
Drug: Befriending Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befriending Therapy (n=9)
Trial: 30567595
Drug: Riociguat (1.0‐2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (1.0‐2.5 mg tid)
Trial: 25035080
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg) for 7 days
Trial: 22884662
Drug: Two vaccinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two vaccinations with Vero cell-derived whole virus non-adjuvanted H5N1 vaccine (7.5 μg HA Antigen A/Vietnam/1203/2004)
Trial: 22884662
Drug: Booster vaccinations
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccinations at 6, 12-15, and 24 months with 7.5 μg A/Indonesia/05/2005
Trial: 22884662
Drug: Booster vaccinations
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccinations with 3.75 μg A/Indonesia/05/2005
Trial: 22884662
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose priming with 7.5 μg A/Vietnam/1203/2004 followed by a 12 month booster (7.5 μg)
Trial: 20418697
Drug: Spanish version
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish version of the SF-8 health-related quality-of-life questionnaire administered before surgery and again 3 months later.
Trial: 20418697
Drug: Spanish version
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish version of the SF-8 health-related quality-of-life questionnaire administered before surgery.
Trial: 20418697
Drug: Spanish version
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish version of the SF-8 health-related quality-of-life questionnaire administered after surgery.
Trial: 20418697
Drug: Spanish version
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish version of the SF-8 health-related quality-of-life questionnaire administered to women.
Trial: 18405411
Drug: Cisatracurium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.1 mg kg‐1)
Trial: 15747810
Drug: Mandible-protruding oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandible-protruding oral appliance
Trial: 7861016
Drug: Stavudine 20
RxNorm normalized name: stavudine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 20 mg twice daily for patients > or = 60 kg
Trial: 7861016
Drug: Stavudine 40
RxNorm normalized name: stavudine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 40 mg twice daily for patients > or = 60 kg
Trial: 7861016
Drug: Stavudine 15
RxNorm normalized name: stavudine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 15 mg twice daily for patients weighing 40-59 kg
Trial: 7861016
Drug: Stavudine 30
RxNorm normalized name: stavudine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 30 mg twice daily for patients weighing 40-59 kg
Trial: 7861016
Drug: Stavudine 10
RxNorm normalized name: stavudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 10 mg twice daily for patients weighing < 40 kg
Trial: 7861016
Drug: Stavudine 20
RxNorm normalized name: stavudine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 20 mg twice daily for patients weighing < 40 kg
Trial: 27917567
Drug: 0.05% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% NaF solution
Trial: 24548981
Drug: Mipomersen 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 50 mg SC
Trial: 24548981
Drug: Mipomersen 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 100 mg SC
Trial: 24548981
Drug: Mipomersen 200
RxNorm normalized name: mipomersen 200 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 200 mg SC
Trial: 23073811
Drug: Micro-implant group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-implant group
Trial: 19526757
Drug: Chaiqin Chengqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaiqin Chengqi Decoction (CQCQD) administered immediately after hospitalization (early-treated group)
Trial: 19526757
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medical therapy (same for both groups)
Trial: 19526757
Drug: Chaiqin Chengqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaiqin Chengqi Decoction (CQCQD) administered 3 days after hospitalization (late-treated group)
Trial: 17296341
Drug: Rimonabant 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 5 mg once daily
Trial: 17296341
Drug: Rimonabant 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 20 mg once daily
Trial: 11681436
Drug: Quantitative culture
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative culture of the subcutaneous catheter segment using roll-plate and sonication methods
Trial: 10216370
Drug: Antirejection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antirejection therapy for Group I (10 patients) for 7 days
Trial: 10216370
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy for Group II (20 patients) for 2 weeks
Trial: 7523479
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies to LH
Trial: 28365225
Drug: Two-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose regimen at 0 and 3 months (group 1)
Trial: 28365225
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose at 0 months (group 2)
Trial: 28365225
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose at 0 months and a booster at 12 months (group 3)
Trial: 25473078
Drug: Proton Pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Pump Inhibitor (PPI) for 8 weeks
Trial: 18399039
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and cognitive therapy (CT)
Trial: 18399039
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and interpersonal therapy (IPT)
Trial: 15472659
Drug: Short-term nonsteroidal
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term nonsteroidal anti-inflammatory drugs and self-care instructions (palliative care group)
Trial: 15472659
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs, self-care instructions, and occlusal appliance and mobilization therapy (physical medicine group)
Trial: 2507061
Drug: Captopril (25‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25‐100 mg/day for 12 months, average dose 40 mg daily during the second six months)
Trial: 780037
Drug: Oxprenolol 20
RxNorm normalized name: oxprenolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 20 mg three times daily, increased to 40 and 80 mg if SDP exceeded 89 mm Hg
Trial: 780037
Drug: Propranolol 20
RxNorm normalized name: propranolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 20 mg three times daily, increased to 40 and 80 mg if SDP exceeded 89 mm Hg
Trial: 31278705
Drug: Intra-articular NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular NSAID Ketorolac injection
Trial: 31278705
Drug: Intra-articular Hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular Hyaluronic acid injection
Trial: 24832381
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori treatment group (n=11)
Trial: 24050956
Drug: Talactoferrin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talactoferrin (1.5 g p.o. BID)
Trial: 19815148
Drug: Heavy orthodontic
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy orthodontic force of 225 g
Trial: 19815148
Drug: Buccal surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal surface
Trial: 15328177
Drug: Ep-CAM protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ep-CAM protein (400 microg/dose)
Trial: 15328177
Drug: Anti-Id antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-Id antibody (500 microg/dose)
Trial: 11210403
Drug: Oxycodone, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone, 5 mg p.o. Q4H and levofloxacin, 500 mg p.o. 1 hour after starting oxycodone
Trial: 11210403
Drug: Levofloxacin, 500
RxNorm normalized name: LevoFLOXacin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin, 500 mg p.o. alone
Trial: 9468210
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (25 mg/min IA)
Trial: 9468210
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (oral therapy for 4 weeks)
Trial: 9468210
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (acute treatment)
Trial: 9468210
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (chronic treatment)
Trial: 28796130
Drug: Agonist-Antagonist (A-A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agonist-Antagonist (A-A) superset configuration
Trial: 26722513
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (chemotherapy plus DC/CIK immunotherapy)
Trial: 19073787
Drug: Rosiglitazone, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone, 3 mg/m²/d for 16 weeks
Trial: 17042890
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) as an adjunct to pharmacological treatment
Trial: 8588058
Drug: Trimipramine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine alone 200 mg/d (group 1)
Trial: 8588058
Drug: Trimipramine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine (200 mg/d) and additional serial partial sleep deprivation (3x/week) (group 2)
Trial: 6165205
Drug: 0.025% budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% budesonide ointment
Trial: 6165205
Drug: 0.025% fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% fluocinolone acetonide ointment
Trial: 6165205
Drug: 0.010% budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.010% budesonide ointment
Trial: 31747132
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (empagliflozin and canagliflozin)
Trial: 30111333
Drug: F@ce™ intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F@ce™ intervention (8-week family-centred intervention with goal setting, problem-solving strategies, daily reminders, and self-rated follow-ups via SMS)
Trial: 27394383
Drug: COPE intervention
RxNorm normalized name: Copernicia prunifera whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPE intervention (10 in-home occupational therapy visits, 1 in-home visit, and 1 telephone contact by an advanced practice nurse)
Trial: 19484170
Drug: Risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg once weekly for 8 weeks
Trial: 18787216
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg once daily)
Trial: 18787216
Drug: Isoniazid (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (300 mg daily)
Trial: 22417569
Drug: Heated and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated and humidified high-flow oxygen therapy (HHFO₂)
Trial: 22417569
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy (no humidification)
Trial: 15800921
Drug: Soy supplement
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplement with isoflavones (soy+IF)
Trial: 15800921
Drug: Soy supplement
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplement (both soy+IF and soy-IF)
Trial: 10588212
Drug: High endotoxin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High endotoxin levels (beyond 50 pg/ml)
Trial: 7047002
Drug: Prednisone plus
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone plus 'triple‐treatment' (vitamin D2 45000 iu twice weekly, sodium fluoride 50 mg and calcium phosphate 4.5 g daily)
Trial: 31868983
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) at 2 L/min
Trial: 31868983
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) at 4 L/min
Trial: 31868983
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) at 6 L/min
Trial: 31868983
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) at 8 L/min
Trial: 29924955
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus sodium thiosulfate (20 g/m² intravenously over 15 minutes, 6 hours after cisplatin)
Trial: 29924955
Drug: Cisplatin alone
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin alone (80 mg/m² over 6 hours)
Trial: 12243243
Drug: Hylan B
RxNorm normalized name: hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan B gel dressing
Trial: 12243243
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no gel dressing)
Trial: 8549224
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (SCH) 5,000 U every 12 hours
Trial: 8549224
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of pneumatic compression stockings (PCS) and subcutaneous heparin (SCH)
Trial: 1986565
Drug: Enalapril (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (angiotensin I converting enzyme inhibitor)
Trial: 6134626
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal suspension (50 g charcoal)
Trial: 31201785
Drug: Azithromycin treatment
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin treatment for 28 days
Trial: 11338314
Drug: Untreated candidates
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untreated candidates for drug treatment
Trial: 9544892
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids (budesonide or beclomethasone)
Trial: 9544892
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (non-steroid treated)
Trial: 8290193
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (100 micrograms at induction, 25 micrograms boluses after 45 and 90 minutes)
Trial: 8290193
Drug: Oral piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral piroxicam (40 mg)
Trial: 6985729
Drug: 5FU +
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5FU + Mito C (20 mg/m2 IV bolus every 8 weeks)
Trial: 6985729
Drug: 5FU +
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5FU + MeCCNU (150 mg/m2 orally every 8 weeks)
Trial: 30203746
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of zoledronic acid combined with oral medication of cinobufagin
Trial: 24976202
Drug: Albendazole and
RxNorm normalized name: Albendazole and ivermectin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole and antiepileptics
Trial: 24976202
Drug: Antiepileptics only
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptics only (Control)
Trial: 20814335
Drug: Quercetin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (2000 mg)
Trial: 16038841
Drug: Balneotherapy (BT)
RxNorm normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapy (BT) + 1000 mg naproxen (NSAID)
Trial: 16038841
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg naproxen (NSAID)
Trial: 7853167
Drug: OPC-31260 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-31260 (3, 15, 30, 60, 100, and 200 mg)
Trial: 7853167
Drug: OPC-31260 (60-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-31260 (60-200 mg)
Trial: 7853167
Drug: OPC-31260 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-31260 (100 and 200 mg)
Trial: 7853167
Drug: OPC-31260 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-31260 (200 mg)
Trial: 1955232
Drug: levamisole 5
RxNorm normalized name: levamisole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levamisole 5 mg/kg body weight on 3 consecutive days every 2 weeks for a period up to 5 months
Trial: 6816006
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 25 or 50 mg/kg body weight twice a day for 5 days